Tweet
Chest. Repair of lipopolysaccharide-induced acute lung injury in mice by endothelial progenitor cells, alone and in combination with simvastatin
[Source: Chest, full text: (LINK). Abstract, edited.]
------
Original Research | March 28, 2013
Repair of lipopolysaccharide-induced acute lung injury in mice by endothelial progenitor cells, alone and in combination with simvastatin
Hao Li; Yong Qiang; Lian Wang; Gaoming Wang; Jun Yi; Hua Jing; Haiwei Wu
Author and Funding Information: Department of Cardiothoracic Surgery, Jinling Hospital, Clinical Medicine School of Nanjing University (Li, Qiang, Lian Wang,Yi, Jing, Wu); Xuzhou Central Hospital, Department of Cardiothoracic Surgery (Gaoming Wang).
Corresponding author: Haiwei Wu, 305 Zhongshan East Road, Nanjing, China. E-mail: wuhaiweicts@163.com.
Funding information: This study was supported by research grants from the Natural Science Foundation of China (NSFC).
Chest. 2013. doi:10.1378/chest.12-2429 - Published online
Abstract
Background:
Endothelial progenitor cells (EPCs) are involved in endothelium repair of acute lung injury (ALI). Numerous studies have demonstrated that statins can promote EPCs function in vitro and in vivo; therefore, the purpose of this study was to determine whether simvastatin enhances the function of EPCs participating in the repair of ALI.
Methods:
BALB/C mice were initially pretreated with simvastatin by intraperitoneal administration 24 h before, and again at the time of, intratracheal instillation of lipopolysaccharide (LPS), and subsequently treated with EPCs by intravenous transplantation 2 h later. The effects of capillary permeability, endothelium repair, and inflammatory cytokines were measured.
Results:
This study revealed that both simvastatin administration and EPCs transplantation can reduce the severity of LPS-induced ALI in mice, and the effect can be further improved by combining the 2 therapies.
Conclusion:
The administration of simvastatin and EPCs transplantation can reduce the severity of LPS-induced ALI in mice, and improvement is moderately enhanced in some respects when EPCs transplantation is combined with simvastatin administration. The beneficial role of simvastatin on EPCs may be a component of its pleiotropic effects. Although the exact mechanism remains unknown, the combined administration of simvastatin and EPCs transplantation may be a potentially important cell-based, inflammatory-mediated therapy for patients with ALI/ARDS.
-Repair of lipopolysaccharide-induced acute lung injury in mice by endothelial progenitor cells, alone and in combination with simvastatin
Hao Li; Yong Qiang; Lian Wang; Gaoming Wang; Jun Yi; Hua Jing; Haiwei Wu
Author and Funding Information: Department of Cardiothoracic Surgery, Jinling Hospital, Clinical Medicine School of Nanjing University (Li, Qiang, Lian Wang,Yi, Jing, Wu); Xuzhou Central Hospital, Department of Cardiothoracic Surgery (Gaoming Wang).
Corresponding author: Haiwei Wu, 305 Zhongshan East Road, Nanjing, China. E-mail: wuhaiweicts@163.com.
Funding information: This study was supported by research grants from the Natural Science Foundation of China (NSFC).
Chest. 2013. doi:10.1378/chest.12-2429 - Published online
Abstract
Background:
Endothelial progenitor cells (EPCs) are involved in endothelium repair of acute lung injury (ALI). Numerous studies have demonstrated that statins can promote EPCs function in vitro and in vivo; therefore, the purpose of this study was to determine whether simvastatin enhances the function of EPCs participating in the repair of ALI.
Methods:
BALB/C mice were initially pretreated with simvastatin by intraperitoneal administration 24 h before, and again at the time of, intratracheal instillation of lipopolysaccharide (LPS), and subsequently treated with EPCs by intravenous transplantation 2 h later. The effects of capillary permeability, endothelium repair, and inflammatory cytokines were measured.
Results:
This study revealed that both simvastatin administration and EPCs transplantation can reduce the severity of LPS-induced ALI in mice, and the effect can be further improved by combining the 2 therapies.
Conclusion:
The administration of simvastatin and EPCs transplantation can reduce the severity of LPS-induced ALI in mice, and improvement is moderately enhanced in some respects when EPCs transplantation is combined with simvastatin administration. The beneficial role of simvastatin on EPCs may be a component of its pleiotropic effects. Although the exact mechanism remains unknown, the combined administration of simvastatin and EPCs transplantation may be a potentially important cell-based, inflammatory-mediated therapy for patients with ALI/ARDS.
------